• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of olaparib in patients with advanced gastric cancer.

作者信息

Mo Miao, Yang Jianing, Zhu Xiaodong, Zhu Ji

机构信息

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

出版信息

Lancet Oncol. 2018 Feb;19(2):e75. doi: 10.1016/S1470-2045(18)30023-8.

DOI:10.1016/S1470-2045(18)30023-8
PMID:29413476
Abstract
摘要

相似文献

1
Use of olaparib in patients with advanced gastric cancer.奥拉帕利在晚期胃癌患者中的应用。
Lancet Oncol. 2018 Feb;19(2):e75. doi: 10.1016/S1470-2045(18)30023-8.
2
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.奥拉帕利联合紫杉醇治疗一线治疗后进展的晚期胃癌患者（GOLD）：一项双盲、随机、安慰剂对照、III 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1637-1651. doi: 10.1016/S1470-2045(17)30682-4. Epub 2017 Nov 2.
3
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.随机、双盲 II 期临床试验，前瞻性按 ATM 蛋白水平分类，以评估奥拉帕利联合紫杉醇治疗复发性或转移性胃癌患者的疗效和耐受性。
J Clin Oncol. 2015 Nov 20;33(33):3858-65. doi: 10.1200/JCO.2014.60.0320. Epub 2015 Aug 17.
4
Use of olaparib in patients with advanced gastric cancer - Authors' reply.奥拉帕利在晚期胃癌患者中的应用——作者回复
Lancet Oncol. 2018 Feb;19(2):e76. doi: 10.1016/S1470-2045(18)30030-5.
5
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.奥拉帕利单药疗法在晚期乳腺癌、卵巢癌或输卵管癌患者中与卡铂和紫杉醇联合使用后的长期安全性及抗肿瘤活性
Br J Cancer. 2015 Jul 28;113(3):396-402. doi: 10.1038/bjc.2015.256. Epub 2015 Jul 16.
6
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.奥拉帕利联合化疗治疗复发性铂类敏感卵巢癌：一项随机 2 期临床试验。
Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4.
7
Targeted therapies: SOLO2 confirms olaparib maintenance in ovarian cancer.靶向治疗：SOLO2试验证实奥拉帕利可用于卵巢癌的维持治疗。
Nat Rev Clin Oncol. 2017 Oct;14(10):586-587. doi: 10.1038/nrclinonc.2017.130. Epub 2017 Aug 16.
8
Missing a GOLDen opportunity in gastric cancer.错失胃癌治疗的绝佳时机。
Lancet Oncol. 2017 Dec;18(12):1561-1563. doi: 10.1016/S1470-2045(17)30719-2. Epub 2017 Nov 2.
9
[Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].奥拉帕尼增强紫杉醇对4T1乳腺癌的抗肿瘤作用
Yao Xue Xue Bao. 2016 Jun;51(6):907-12.
10
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.一项针对BRCA1或BRCA2突变的HER2阴性晚期乳腺癌一线治疗的I期试验，随后进行两个周期卡铂-奥拉帕利联合治疗，然后奥拉帕利单药治疗与卡培他滨对比的随机II期试验（REVIVAL）：一项随机对照试验的研究方案。
Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0.

引用本文的文献

1
Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.精准肿瘤学和免疫检查点抑制剂时代的DNA损伤修复治疗靶点
J Immunother Precis Oncol. 2022 Dec 2;6(1):31-49. doi: 10.36401/JIPO-22-15. eCollection 2023 Feb.
2
Gastric cancer: a comprehensive review of current and future treatment strategies.胃癌：当前和未来治疗策略的综合综述。
Cancer Metastasis Rev. 2020 Dec;39(4):1179-1203. doi: 10.1007/s10555-020-09925-3. Epub 2020 Sep 7.
3
State-of-the-art strategies for targeting the DNA damage response in cancer.
针对癌症中 DNA 损伤反应的最新策略。
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104. doi: 10.1038/s41571-018-0114-z.